UNSPSC 51273001: Alfentanil

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1N74HM2BS7, chemically known as propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl- but generally known as alfentanil, which bears US NIH Compound Identifier 51263. Alfentanil most often comes in base and hydrochloride forms.

UNSPSC 51273001 Alfentanil, a Commodity code, covers pharmaceutical supply procurement by state and local health agencies, though recent sourced opportunities show limited direct alfentanil solicitation and instead reflect broader pharmaceutical procurement patterns across naloxone, generic multi-source drugs, and OTC products. State and local governments acquire controlled substances and emergency medical supplies through this code via county health departments, state HHS commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The issuing bodies sourcing under related pharmaceutical codes include county health systems (Seminole County, Florida), state health and human services departments (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in multiple states including Oregon). Vendors must navigate DEA registration, cGMP certification, Drug Supply Chain Security Act compliance, comprehensive insurance requirements, and strict delivery and cold-chain logistics for controlled pharmaceutical products.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the procurement requires E-Verify compliance, workers' compensation and liability insurance, and includes a three-month probationary termination clause with potential FEMA funding contingencies. The Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) as exploratory market research on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative, signaling future procurement intent but carrying no immediate award value. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required NDC compliance, $5 million commercial general liability insurance, and 3 percent administrative fees on all contract purchases.